Liquid biopsy may have a supplementary role in the diagnosis of ALK-positive NSCLC, particularly during the later period after diagnosis, and platelets may be useful for predicting treatment outcomes of ALK inhibitors. This evidence concerns the gene ALK and non-small cell lung carcinoma.